Log InSign Up
MissionModelBlogPricingVitaeLeaderboardLibrary

ACRV

StatementStatement RatioRatio
NewsNews
Yahoo Finance Google Finance Market Beat Bar Chart

Acrivon Therapeutics Inc. Common Stock (NASDAQ:ACRV)

Real-time price： | Most recent change：0.00%

Acrivon Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines which matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics. The company's lead candidate includes ACR-368. Acrivon Therapeutics Inc. is based in WATERTOWN, Mass....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 13 June 2026

Blog+More

The Trump administration postpones increasing 25% to 30% tariffs on $250 billion Chinese imports after China extends an olive branch to de-escalate Sino-American tariff tension.

Jacob Miramar

2019-10-01 11:33:00 Tuesday ET

The Trump administration postpones increasing 25% to 30% tariffs on $250 billion Chinese imports after China extends an olive branch to de-escalate Sino-American tariff tension.

The Trump administration postpones increasing 25% to 30% tariffs on $250 billion Chinese imports after China extends an olive branch to de-escalate Sino-Ame

+See More

Former New York Times team journalist and Pulitzer Prize winner Charles Duhigg delves into how we can change our lives for the better by mastering our habits from day to day.

Monica McNeil

2025-06-05 00:00:00 Thursday ET

Former New York Times team journalist and Pulitzer Prize winner Charles Duhigg delves into how we can change our lives for the better by mastering our habits from day to day.

Former New York Times team journalist and Pulitzer Prize winner Charles Duhigg describes, discusses, and delves into how we can change our respective lives

+See More

The Trump team now aims to make progress on health care, infrastructure, social welfare, and immigration.

Monica McNeil

2018-01-06 07:32:00 Saturday ET

The Trump team now aims to make progress on health care, infrastructure, social welfare, and immigration.

Subsequent to the Trump tax cuts for Christmas in December 2017, the one-year-old Trump presidency now aims to make progress on health care, infrastructure,

+See More

CEO overconfidence and corporate performance

Laura Hermes

2022-11-05 11:32:00 Saturday ET

CEO overconfidence and corporate performance

CEO overconfidence and corporate performance Malmendier and Tate (JFE 2008, JF 2005) argue that overconfident CEOs are more likely to initiate mergers an

+See More

Chicago finance professor Raghuram Rajan suggests that free markets need populist support against an unholy alliance of private-sector and state elites.

John Fourier

2019-05-21 12:37:00 Tuesday ET

Chicago finance professor Raghuram Rajan suggests that free markets need populist support against an unholy alliance of private-sector and state elites.

Chicago finance professor Raghuram Rajan shows that free markets need populist support against an unholy alliance of private-sector and state elites. When a

+See More

Internal capital markets and financial constraints

Charlene Vos

2022-10-15 09:34:00 Saturday ET

Internal capital markets and financial constraints

Internal capital markets and financial constraints Duchin (JF 2010) empirically finds that multidivisional firms with robust internal capital markets ret

+See More